$Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer$

Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

BACKGROUND AND OBJECTIVES: Since previous studies have indicated there are improvements in overall survival, the aim of this phase II clinical study was to evaluate docetaxel every three weeks plus prednisone as first-line chemotherapy for treatment of hormone-refractory metastatic prostate cancer (...

Full description

Bibliographic Details
Main Authors:	Abd El Halim Mohamed Abu-Hamar, Saleh Mansour, Mohamed El Shebiney, Naser Mohamed Abd El Bary, Emad Sadaka, Alaa Maria
Format:	Article
Language:	English
Published:	Elsevier 2010-07-01
Series:	Hematology/Oncology and Stem Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S1658387610500220

Similar Items

A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
by: Tie Zhou, et al.
Published: (2015-01-01)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
by: E. A. Wist, et al.
Published: (2012-01-01)

Clinical Study of Docetaxel, Prednisone and Bevacizunab in the Treatment of Hormone Refractory Prostate Cancer
by: Theodore D. Koreckij, et al.
Published: (2015-06-01)

Advanced non-small cell lung cancer in elderly patients: The standard every 3-weeks versus weekly paclitaxel with carboplatin
by: Hala Mohamed El-Shenshawy, et al.
Published: (2012-10-01)

Weekly docetaxel in an elderly patient with refractory classic Kaposi sarcoma
by: Rongbo Lin
Published: (2016-06-01)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
by: Hu L, et al.
Published: (2020-06-01)

The Effects of Prednisone and Prednisone Plus Ultralow-dose Aspirin on Coagulation Parameters in Healthy Dogs
by: O'Kell, Allison Louise
Published: (2014)

A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
by: Naser Abd El Bary, et al.
Published: (2010-01-01)

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
by: Andrea Necchi, et al.
Published: (2020-11-01)

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer
by: R Collins, et al.
Published: (2007-01-01)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
by: Se Ryeon Lee, et al.
Published: (2019-11-01)

Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
by: Alaa Mohamed Maria, et al.
Published: (2018-06-01)

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
by: Seung Tae Kim, et al.
Published: (2019-04-01)

Corrigendum: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. Kasr El-Aini J Clin Oncol Nucl Med. 2009; 5(3-4): 11-17.
by: Naser Abd El Bary, et al.
Published: (2019-06-01)

Exploring Critical Success Factors for Public Private Partnership Case Study: The Educational Sector in Egypt
by: Riham Helmy, et al.
Published: (2020-11-01)

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
by: Zhenyu Yang, et al.
Published: (2021-08-01)

Efficacy of central venous catheter in pleurodesis in refractory hepatic hydrothorax
by: Adel H.A Ghoneim, et al.
Published: (2019-01-01)

Optimization of Synthesis Parameters for Mesoporous Shell Formation on Magnetic Nanocores and Their Application as Nanocarriers for Docetaxel Cancer Drug
by: Mansour Alhoshan, et al.
Published: (2013-05-01)

Towards using BPM Patterns in Requirements Elicitation
by: AbdElKader, Mohamed AbdElRazik Mansour
Published: (2011)

Functional outcome after Swenson′s operation for Hirshsprung′s disease
by: Gad El-Hak Nabil, et al.
Published: (2010-01-01)

Self-expandable metallic stents (SEMS) in esophageal varices post-band ulcer refractory bleeding: a retrospective study
by: Osama Elbahr, et al.
Published: (2021-05-01)

Serum levels of angiopoietin-2 and vascular endothelial growth factor in severe refractory asthma
by: Mohamed Hantera, et al.
Published: (2014-10-01)

Docetaxel (Tautax) in the treatment of hormone-refractory prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-02-01)

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
by: Hugo Ford, et al.
Published: (2015-07-01)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
by: G. Gravis, et al.
Published: (2020-07-01)

Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial
by: Lydia T de Moraes Falcão, et al.
Published: (2020-06-01)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
by: John Devin Peipert, et al.
Published: (2020-01-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Study of infective endocarditis in Alexandria main university hospitals
by: Mohamed Sadaka, et al.
Published: (2013-12-01)

Effect of sofosbuvir plus daclatasvir on virological response and liver function tests as a line of treatment for HCV related cirrhosis (a prospective cohort study)
by: Omaima Mohamed Ali, et al.
Published: (2020-07-01)

Physical indicators for pollution detection in terrestrial and aquatic ecosystems
by: Alaa Zaghloul, et al.
Published: (2019-07-01)

Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer
by: Wiseman Janice, et al.
Published: (2011-05-01)

Evaluation of Bax and Bak Gene Mutations and Expression in Breast Cancer
by: Naglaa Mohamed Kholoussi, et al.
Published: (2014-01-01)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
by: Victoria J Sinibaldi
Published: (2008-01-01)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
by: Javier Puente, et al.
Published: (2019-08-01)

Prednisone in Duchenne Dystrophy
by: J Gordon Millichap
Published: (1991-04-01)

Carbamazepine Rash and Prednisone
by: J Gordon Millichap
Published: (1991-02-01)

Effects of Prednisone or Prednisone with Ultralow-Dose Aspirin on the Gastroduodenal Mucosa of Healthy Dogs
by: Graham, Allison Heather
Published: (2014)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
by: Xue-Song Sun, et al.
Published: (2020-08-01)

Technological properties of high alumina refractories with different phosphoric acid contents
by: Basel Nour El-Din Ali Shalaby, et al.
Published: (2018-11-01)